Supplemental Digital Content 3. Table. Characteristics of intensive support and thoracic echocardiography performed in patients with PMIS-TS

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Characteristics\*** | **Case 1** | **Case 2** | **Case 3** | **Case 4** | **Case 5** | **Case 6** | **Case 7** | **Case 8** | **Case 9** | **Case 10** | **Case 11** |
| PICU indication | Apnea | SE/ ARF | HI/ ARF | HI | HI | HI | HI/ ARF | HI/ ARF | HI/ RD | HI | RD |
| Renal replacement therapyα | + | - | - | - | - | - | - | - | - | - | - |
| MODS | + | + | + | + | + | + | + | + | + | + | + |
| ARDS ∆ | + | + | - | - | - | - | + | + | - | - | - |
| Pneumonia | + | + | + | - | - | + | + | + | + | + | + |
| Circulatory shock |  |  |  |  |  |  |  |  |  |  |  |
| Cardiogenic/ Septic | -/+ | -/+ | +/- | +/- | -/- | -/- | +/- | +/+ | +/- | -/- | -/- |
| Vasoactive drugs | Yes | Yes | Yes | Yes | No | No | Yes | Yes | Yes | No | No |
| Blood components | + | + | - | - | - | - | - | + | - | - |  |
| Medicines |  |  |  |  |  |  |  |  |  |  |  |
| Corticosteroids | + | + | + | + | + | + | + | + | + | + | + |
| IgIV single dose 2g / kg | - | + | + | + | + | + | + | + | + | + | + |
| ASA | - | - | + | + | + | + | + | + | + | + | + |
| Enoxaparin dose 3mg / kg | - | - | + | + | + | + | + | + | + | + | + |
| EF (%) | 59 | 30 | 77 | 69 | 65 | 65 | 61 | 59 | 62 | 68 | 62 |
| DDLV in mm | 24 | 42 | 48 | 31 | 32 | 26 | 42 | 38 | 38 | 35 | 49 |
| SDLV in mm | 15 | 21 | 26 | 19 | 21 | 17 | 29 | 29 | 14 | 20 | 14 |
| CO in L/ min | 2 | 1.8 | 3.9 | 2.8 | 3.1 | 2.6 | 2.9 | 2.1 | 3.5 | 3.2 | 3.0 |
| LCA (z score) | - | - | +1.33 | +3.16 | +3.0 | - | +1.95 | +5.8 | +9.77 | - | - |
| RCA (z score) | - | - | +2.72 | +4.15 | +1,98 | - | +3.9 | +5.6 | - | +5.44 | +2.66 |
| ADC (z score) | - | - | - | - | - | - | - | - | - | - | +5.12 |

\*SE: **Status epilepticus** ARF: acute respiratory failure; MODS: Multiple organ dysfunction syndrome ; ARDS:Acute respiratory distress syndrome ; ASA: acetylsalicylic acid;RD: respiratory distress, both moderate; HI: Hemodynamic instability; ADC: Anterior descending coronary artery; RCA: Right coronary artery; LCA: Left coronary artery. Comorbity: Patient1: Extreme prematurity, chronic neonatal lung disease and ischemic hypoxic encephalopathy; Patient 2: Post-traumatic chronic encephalopathy and chronic respiratory failure does not depend on oxygen, tracheostomy; Patient 3.7 and 8: overweight; Patient 9; mild asthma and obesity; Patient 10: mild asthma and obesity; Patient 11: obesity; MODS: patient 1: Respiratory, cardiovascular, renal, neurological, hematological; Patient 2: Neurological, respiratory, cardiovascular, hematological; Patient 3: Cardiovascular, hepatic and hematological; Patient 4, 5, 6, 9, 10 and 11: Cardiovascular, hepatic and hematological; Patient 7: Cardiovascular, respiratory and hematological; Patient 8: Cardiovascular, renal, respiratory and hematological; Expansion with unbalanced crystalloids: Patient 1: 40ml / kg; Patient 2: 80ml / kg; Patient 3: 30ml / kg; Patient: 40ml / kg; Patient 6: 50ml / kg; Patient 7: 30ml / kg; Patient 8: 30 ml / kg; Patient 9: 20 ml / kg; Patient 10: 40 ml / kg; Patient 11: 40 ml / kg; Blood components: Patient 1: red blood cell concentrate 10ml / kg 2x; Patient 2: red blood cell concentrate 10ml / kg, 2x and fresh frozen plasma 10ml / kg 1x and Cryoprecipitate 10ml / kg 1x; Patient 8: red blood cell concentrate 10ml / kg 1x; Corticosteroids and ASA: Patient 1: hydrocortisone 100 mg / m² / day 4 days; Patient 2: hydrocortisone 100 mg / m² / day 5 days; Patient 3: methylprednisolone 1 mg / kg / day and ASA of 30 mg / kg / day; Patient4: methylprednisolone 1 mg / kg / day and ASA of 30 mg / kg / day; Patient 5: methylprednisolone 1 mg / kg / day and ASA of 30 mg / kg / day; Patient 6: methylprednisolone 1 mg / kg / day and ASA of 30 mg / kg / day; Patient 7: methylprednisolone 1 mg / kg / day and ASA of 80 mg / kg / day; Patient 8: methylprednisolone 1 mg / kg / day and ASA of 30 mg / kg / day; Patient 9: methylprednisolone 1 mg / kg / day and ASA of 80 mg / kg / day; Patient 10: methylprednisolone 1 mg / kg / day and ASA of 30 mg / kg / day; Patient 11: methylprednisolone 1 mg / kg / day and ASA of 30 mg / kg / day; Ejection fraction; systolic diameter of the left ventricle; diastolic diameter of the left ventricle; cardiac output. Other findings: Patient 1: pericardial stroke (<2mm); Patient 2: slight dilation of the left atrium and mild mitral regurgitation; Patient 4: slight tricuspid and pulmonary reflux without repercussions; Patient 5: slight tricuspid and pulmonary reflux without repercussions; Patient 6: thickened pericardium and diffuse stroke and mild degree in the posterior region (5.6 mm); Patient 7: mild stroke in the anterior region (3.5 mm) without signs of restriction; Patient 8: diffuse stroke and mild degree in the anterior region, mainly (4.4 mm) without signs of restriction; Patient 9: massive pericardial stroke (16mm) in the anterior region, without signs of restriction; Patient 10: small pericardial stroke (3 mm) in the posterior region; Patient 11: mild dilation of the left chambers, moderate dilation of the left chambers and moderate tricuspid and aortic insufficiency. ECG: Normal in patients 1, 2, 3.7, 8 and 10; Patient 3: sinus bradycardia; Patient 4: T-wave inversion in D1, D2, AVF, V1 and V2; Patient 5: Supra ST (0.5 mm) in D1, D2, D3, V1, V2, V4, V5 AND AVF; Patient 9: sinus bradycardia; Patient 11: left ventricular overload.α In patient 1, peritoneal dialysis was indicated, however it was not performed due to hemodynamic instability; Δ According to the PALICC criteria, 2015.